Table 2. Viral responses in HCV/HIV-coinfected patients treated with pegIFN α-2a (135 µg/week) plus ribavirin (800 mg/day).
| RVR | EVR | ETR | SVR | Relapse | |
| ITT analysis (n = 58), no. (%) | 28 (48.3) | 50 (86.2) | 43 (74.1) | 33 (56.9) | 10/43 (23.2) |
| CI95 (%) | (35.5–61.1) | (77.4–95.0) | (62.5–85.7) | (43.8–70.0) | (10.1–36.4) |
| ≤800000 IU/mL (n = 37), no. (%) | 23 (62.2) | 33 (89.2) | 27 (73) | 24 (64.9) | 3/27 (11.1) |
| >800000 IU/mL (n = 21), no. (%) | 5 (23.8) | 17 (81.0) | 16 (76.2) | 9 (42.9) | 7/16 (43.8) |
| n = 54 | n = 53 | n = 47 | n = 47 | n = 43 | |
| Per-protocol analysis, no. (%) | 28 (51.9) | 50 (94.3) | 43 (91.4) | 33 (70.2) | 10 (23.2) |
| CI95 (%) | (38.1–65.6) | (87.9–100) | (83.2–100) | (56.6–83.8) | (10.1–36.4) |
| ≤800000 IU/mL, no. (%) | 23 (67.6) | 33 (97.1) | 27 (93.1) | 24 (82.8) | 3 (11.1) |
| n = 34 | n = 34 | n = 29 | n = 29 | n = 27 | |
| >800000 IU/mL, no. (%) | 5 (25.0) | 17 (89.5) | 16 (88.9) | 9 (50.0) | 7 (43.8) |
| n = 20 | n = 19 | n = 18 | n = 18 | n = 16 |
ITT: intention to treat. RVR: rapid virological response. EVR: early virological response. ETR: end of treatment response. SVR: sustained virological response.